AI-assisted international press reviewPress review

Rovensa Next Launches Myndra: A Biostimulant for Exceptional Fruits!

Rovensa Next launches Myndra: the revolutionary biostimulant derived from Ascophyllum nodosum algae to enhance fruit quality in perennial crops. Through a cold extraction process without chemicals, it improves firmness (+19%), sugar content (+10%), and fruit weight (+19%), while increasing marketable yield. Certified by EU Regulation 2019/1009, Myndra aligns with a sustainable strategy for innovative and environmentally friendly agriculture. Trials on stone fruits, pome fruits, citrus, and table grapes confirm these benefits, enhancing the value of premium harvests. A major breakthrough for agritech!

SEPEHR ACHARD, Source: Igronews, published under the title "Rovensa Next Launches Myndra Biostimulant to Enhance Fruit Q..." - 10 December 2025

Thiess Drives Queensland's Largest Copper Mine Forward

Thiess and Harmony join forces for the Eva copper mine project in Australia: a 700 million Australian dollar contract for earthworks, construction, and mining services over five years. This strategic partnership emphasizes sustainability, energy efficiency, and local development, promoting employment, training for Indigenous communities, and a transition to clean energy. Initial works have been underway since May 2025, with mining services planned until 2031.

Source: Grupoacs, published under the title "Thiess to boost Queensland's largest copper mine" - 10 December 2025

Thiess Wins $700 Million Contract for Eva Copper Mine

Thiess and Harmony join forces to revolutionize sustainable copper extraction at the Eva Copper project in Australia. With extensive work planned over five years, valued at A$700 million, this partnership emphasizes efficiency, safety, and local development, while promoting employment and indigenous communities for a greener future. Innovative benchmarks are on the horizon for the mining industry!

Source: Hochtief, published under the title "Thiess secures A$700 million alliance agreement with Harmony..." - 10 December 2025

GSK'227 Receives Orphan Drug Designation for SCLC from FDA

GSK has received orphan drug designation for risvutatug rezetecan in the treatment of small cell lung cancer (SCLC). Supported by preliminary clinical data showing durable responses in patients with extensive-stage disease, this advancement highlights the urgency in addressing an aggressive cancer with high relapse rates and a grim prognosis. GSK's fifth regulatory designation accelerates the development of this promising candidate for solid tumors, paving the way for transformative treatments.

Source: Gsk, published under the title "GSK’227, a B7-H3-targeted antibody-drug conjugate, granted O..." - 10 December 2025

Thiess and Harmony Partner for the Eva Copper Mine Project in Australia

Thiess and Harmony join forces for the Eva Copper Mine in Australia: a $700 million contract for earthworks, construction, and mining services over five years. This strategic partnership emphasizes sustainability, efficiency, and energy transition, with a strong commitment to local employment, indigenous community development, and responsible mining innovation. Initial works have been underway since May 2025, leading to full operations by June 2026.

Source: Cimic - 10 December 2025

First in Australia: North East Link Certified PAS2080

CPB Contractors and the SPARK consortium mark a first in Australia with the North East Link project: the first infrastructure certified PAS2080, the global standard for carbon management across the entire lifecycle. Through a collaborative approach, they integrate 100% renewable electricity, recycled materials in concrete, and a commitment to net zero emissions, demonstrating a real step towards sustainable infrastructure for the benefit of communities.

Source: Cimic, published under the title "North East Link achieves Australian-first sustainability mil..." - 10 December 2025

ExxonMobil Revises Its 2030 Plan for Increased Profits

ExxonMobil announces a revision of its 2030 plan, aiming for a $5 billion increase in profits and growth in cash flow, without raising capital expenditures. The structural cost reduction plan has been raised to $20 billion compared to 2019, while greenhouse gas emission intensity targets are expected to be met as early as 2026.

Source: Exxonmobil, published under the title "ExxonMobil raises its 2030 Plan – transformation delivering ..." - 9 December 2025

CPB Contractors Integrates Broad to Enhance National Projects

CPB Contractors integrates Broad Construction: A strategic merger in 2025 to enhance construction expertise. New projects in key sectors such as education, defense, and health are now under the national banner, while ongoing projects in Western Australia and Queensland remain under the Broad name. This union strengthens capabilities, leverages 30 years of agility and exceptional results, with an unwavering focus on safety and unmatched client benefits. A decisive step for innovation in building.

Source: Cimic, published under the title "Integration strengthens national building capability" - 9 December 2025

AskBio Receives Pioneering Designation for Parkinson's and Heart Failure Therapies in Japan

The SAKIGAKE designation in Japan propels AskBio's innovative gene therapies, such as AB-1005 for Parkinson's disease and AB-1002 for congestive heart failure, accelerating their development and providing concrete hope for patients suffering from these serious chronic conditions, through a pioneering approach that combines advanced biotechnology and expedited regulation. This advancement strengthens the global commitment to targeted and sustainable treatments.

Source: Bayer, published under the title "AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative..." - 9 December 2025

Novartis' Kisqali: 25% of Patients Without Progression After 4 Years

Novartis reveals: Kisqali allows one quarter of patients with advanced HR+/HER2- breast cancer to remain progression-free for at least four years, according to an analysis of the MONALEESA trials. This innovative treatment, unique for its significant overall survival, also reduces the risk of recurrence in early-stage cancer, as shown by NATALEE data. Presented at the San Antonio Symposium 2025.

Source: Novartis, published under the title "1 in 4 metastatic breast cancer patients treated with Novart..." - 9 December 2025

AgrifoodNorth America

Pairwise Shapes the Future of Food with NTG Innovations

As the European Union debates the deregulation of new genomic modification techniques (NGM), the American company Pairwise accelerates its strategic partnerships with Crispr/Cas, including its recent agreement with IRRI. Leveraging its Fulcrum platform and SHARC enzyme, Pairwise promises rapid agricultural innovations that are "non-GMO" – a claim contested in Europe, where these methods are regulated as such. These alliances, involving both public and private actors, could soon shape access to NGM and the arrival of new modified foods on our plates, raising ethical and regulatory questions.

Source: Info Ogm, published under the title "Pairwise façonne l’alimentation du futur à la sauce NTG" - 9 December 2025

Turner Develops Innovative Hospital in Memphis

Regional One Health is transforming Memphis with a state-of-the-art hospital campus in the Edge District, expanding critical care services from trauma and burn care to women's and children's health. With partners like Turner and HDR, this innovative project is generating 3,600 construction jobs and boosting the economy, enhancing access to care and health innovation for the Mid-South. A historic investment for a healthier future.

Source: Grupoacs, published under the title "Turner to develop new Regional One Health hospital in Memphi..." - 9 December 2025

TECVAYLI® and DARZALEX FASPRO®: Promising Advances in Multiple Myeloma Treatment

The results of the MajesTEC-3 study reveal that the combination of TECVAYLI® and DARZALEX FASPRO® offers significant benefits in terms of progression-free survival and overall survival for patients with refractory multiple myeloma, with response rates and minimal residual disease negativity significantly higher than those of standard treatments. Johnson & Johnson is committed to accelerating the approval of this therapeutic combination, which could transform current treatment practices.

Source: J&j - 9 December 2025

Novartis: Ianalumab Extends ITP Control by 45% with Four Monthly Doses

Novartis unveils promising results for ianalumab in ITP: a 45% extension of disease control and a treatment failure time increased by 2.8 times. With sustained platelet response in 62% of patients, this innovative treatment, administered in four monthly doses, could reduce the need for chronic therapy. Presented at ASH and published in the New England Journal of Medicine, it paves the way for improved quality of life for patients.

Source: Novartis, published under the title "Novartis ianalumab significantly extends disease control in ..." - 9 December 2025

Abbott's Lingo on Android: Expanded Access to Real-Time Glucose Monitoring

Abbott's innovation: Lingo, the first over-the-counter biowearable for continuous glucose monitoring, is now available on Android devices. Recent data shows that protein supplementation reduces glucose spikes, particularly in obese individuals, promoting better metabolic health and increased prevention of diabetes and other chronic diseases. Discover how these simple tools are transforming daily habits for sustainable well-being.

Source: Abbott, published under the title "Abbott's Lingo™ Now On Android™, Expanding Access To Real-Ti..." - 9 December 2025

UGL Wins Three Diamond Awards for Its Sustainability Program

UGL triumphs at the 2025 LearnX Awards with three Diamonds for its training program on environmental fundamentals and sustainability. This global recognition celebrates excellence in environmental education, ESG, and skill development to manage risks in large infrastructure projects. Sean Helbig, UGL's sustainability manager, emphasizes: "This reflects our commitment to integrating sustainability into our operations for a greener future." An inspiring advancement for agro-environmental innovation!

Source: Cimic - 9 December 2025

Mars Receives Final Approval and Completes Strategic Acquisition

Mars, a major player in the agri-food sector, has recently received final regulatory approval to complete the acquisition of an innovative company in the food ingredients sector. This move is part of a broader expansion strategy aimed at strengthening its position in the plant protein and sustainable ingredients market, while addressing new consumer expectations for healthy and responsible food products.

Source: Mars Incorporated, published under the title "Mars Receives Final Regulatory Approval and Moves to Close A..." - 9 December 2025

Johnson & Johnson at the J.P. Morgan Healthcare Conference 2026

Johnson & Johnson at the 44th J.P. Morgan Healthcare Conference: Discover their innovative health perspectives! On January 12, 2026, join the live Fireside Chat at 11:15 ET on investor.jnj.com. A real-time audio webcast, with replay available the same day and full recording 48 hours later. Don't miss this major event for industry professionals!

Source: J&j - 9 December 2025

PepsiCo Accelerates Growth with Innovative Agritech in 2026

PepsiCo is accelerating its transformation: Healthy food innovations without additives, cost reductions, and supply chain optimization to boost growth in 2026. With products like Simply NKD Cheetos and Doritos Protein, the company aims for enhanced operating margins and increased returns for shareholders, while engaging partners like Elliott Investment Management. Join us for the Q&A session on December 9, 2025!

Source: Pepsico, published under the title "PepsiCo Announces Priorities to Enhance Shareholder Value an..." - 9 December 2025

Memphis: New Hospital to Boost Regional Health and Economy

Revolutionary Expansion in Memphis: A new hospital campus enhances critical care services, including trauma and oncology, while stimulating the creation of thousands of jobs and economic growth in the Mid-South, marking a significant investment for a healthier future.

Source: Hochtief, published under the title "Memphis Healthcare Builders Team Announced for Regional One ..." - 9 December 2025